Enterprise Value
28.98M
Cash
186M
Avg Qtr Burn
-21.14M
Short % of Float
3.88%
Insider Ownership
6.86%
Institutional Own.
89.11%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OP-1250 (CER antagonist) Details Metastatic breast cancer | Phase 2 Data readout | |
OP-1250 +palbociclib Details Metastatic breast cancer, Breast cancer | Phase 2 Update | |
OP-1250 +ribociclib Details Breast cancer, Metastatic breast cancer | Phase 1b Data readout |